ClinicalTrials.gg
RecruitingNCT07304817COMPARE-VSUpdated May 29, 2026

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

A Phase 2 interventional study of vicadrostat / empagliflozin combination 1 and Spironolactone (drug) in CKD, Cardiovascular Diseases and Heart Failure, sponsored by University Medical Center Groningen. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Primary conditionHeart FailureRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure
Why
  1. The study's listed conditions name Heart Failure, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Medical Center Groningen · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Heart Failure by University Medical Center Groningen — 8 open to participants now, 9 under way, 1 of them phase 3. Heart Failure · University Medical Center Groningen.

Planned enrollment
12th of 18
100 · median 301
Started
2026
with 4 others
Phase 2
5 of 28
1 open now
Registered
24th of 28
by date

Among the 28 studies in Heart Failure by University Medical Center Groningen, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2026, is one of 5 in phase 2, and was the 24th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

8 of the 28 studies in Heart Failure by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Heart Failure by University Medical Center Groningen, or all of them as a file.
02

Study summary

In this study, investigators will compare the effect of vicadrostat combined with empagliflozin with the effect of spironolactone combined with empagliflozin on renal function and changes in protein profiles in blood and urine.

The hypothesis is that the renal and cardiac responses between vicadrostat and spironolactone differ due to mechanistic differences in their mode of action. Spironolactone is a mineralocorticoid receptor antagonist (MRA) and exerts its effect on a receptor, or a type of "receiver," found on various cells. Vicadrostat is an aldosterone synthase inhibitor (ASI) and inhibits aldosterone production. Therefore, both drugs affect aldosterone.

However, studies evaluating the differences between MRAs (such as spironolactone) and ASI (such as vicadrostat) and examining their effects on the kidneys in patients with chronic kidney disease with concurrent cardiovascular disease, and/or heart failure are still lacking.

For this study, all participants will be divided into two groups:

  • Group 1. Participants in this group will receive one tablet of vicadrostat (10 mg) and one tablet of empagliflozin (10 mg) daily for 26 weeks.
  • Group 2. Participants in this group will receive one tablet of spironolactone (25 mg) and one tablet of empagliflozin (10 mg) daily for the first four weeks. Participants in this group will then receive two tablets of spironolactone (50 mg) and one tablet of empagliflozin (10 mg) daily for the remaining 22 weeks. The spironolactone dosage may be adjusted during the study period (from 12.5 to 50 mg) based on blood test results.
Read the detailed description

The hypothesis is that renal and cardiac response to a mineralocorticoid receptor antagonist (MRA) differs from the response to an aldosterone synthase inhibitor (ASi) due to the mechanistic differences in action between these two compounds. However, direct head-to-head comparative studies evaluating the renal, cardiac, and systemic effects of MRAs and ASi in patients with chronic kidney disease (CKD), with concomitant cardiovascular disease (CVD) or heart failure (HF), are lacking.

The main objective of this study in patients with chronic kidney disease with either cardiovascular disease and/or or heart failure is to compare the effects of the ASi, vicadrostat, with the steroidal MRA, spironolactone, on the change in kidney function from baseline to 4 and 26 weeks.

Secondary objectives include

  • Change in renal hemodynamic measurements from baseline to 4 and 26 weeks
  • Changes in plasma and urinary protein profiles and associated pathways from baseline to 4 and 26 weeks

This is a mechanistic trial using an open-label, parallel-group comparative design with 1:1 randomization and blinded endpoint assessment.

Treatment with vicadrostat (Investigational Medicinal Product; IMP 10mg daily) or spironolactone (Comparator IMP; 25-50mg daily) for 26 weeks whilst on empagliflozin (Auxiliary Medicinal Product; AxMP 10mg daily). In half of the enrolled subjects (targeted 50 subjects) renal hemodynamic measurements will be performed at baseline, at 4 and at 26 weeks.

03

Conditions studied

  • CKD
  • Cardiovascular Diseases
  • Heart Failure

Browse trials for

Keywords

  • COMPARE-VS
  • Spironolactone
  • Vicadrostat
  • CKD
  • mineralocorticoid receptor antagonist (MRA)
  • aldosterone synthase inhibitor (ASi)
04

In context

Heart Failure Reclassified

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's planned enrollment of 100 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.

Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provided written and dated for participation prior to trial admission,
  2. Age ≥18 years, female or male
  3. Patients with

    • Heart failure*1 (any ) and *2 between 25-90 mL/min/1.73m2 OR
    • Established cardiovascular disease*3 and eGFR between 25-60 mL/min/1.73m2 OR
    • Established cardiovascular disease and type 2 diabetes and eGFR between 25-90 mL/min/1.73m2
  4. Serum potassium ≤ 5.0 mmol
  5. Currently treated or eligible for treatment with Empagliflozin*4
  6. Not using a MRA or AS inhibitor in the last 6 months prior to enrollment
  7. On stable doses of other guideline directed medical therapies for ≥ 4 weeks prior to enroll-ment
  8. Outpatient.

    • 1 HF is defined as the definition used in the most recent ESC guidelines for HF.
    • 2 eGFR as assessed by the 2009 CKD-EPI without the race coefficient
    • 3 Cardiovascular disease is defined as a history of a myocardial infarction, coronary bypass surgery, PCI, or proven coronary artery disease (e.g. by coronary angiography, CT-scan, etc.)
    • 4 If switching from another SGLT2i to Empagliflozin subjects can be enrolled directly. If the subject is not yet on SGLT2i and starts Empagliflozin enrollment can start 4 weeks later see criteria 8.

Exclusion criteria

Exclusion Criteria:

  1. Inability to understand and sign
  2. Absolute for aldosterone antagonist
  3. Absolute contra-indication for a SGLT2-inhibitor
  4. Heart failure hospitalization, acute coronary syndrome, cardiac surgery, stroke or transient is-chemic attack in the 90 days prior to enrollment
  5. Women who are pregnant, breastfeeding or may be considering pregnancy during the study duration.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Vicadrostat

    daily treatment with Vicadrostat and background Empagliflozin

    Drug: vicadrostat / empagliflozin combination 1

  • Active comparator
    Spironolactone

    daily treatment with Spironlactone and background Empagliflozin

    Drug: Spironolactone (drug)

Interventions

07

What researchers measure

Primary outcomes

  1. Kidney function (eGFR)

    Changes in kidney function as determined by change in eGFR

    Time frame: From baseline to 4 and 26 weeks of treatment.

Secondary outcomes

  1. Renal hemodynamic measurements

    Changes in renal hemodynamic measurements

    Time frame: From baseline to 4 and 26 weeks of treatment

  2. Plasma protein profiles

    Plasma protein profiles via proteomics

    Time frame: From baseline to 4 and 26 weeks of treatment

  3. Urinary protein profiles

    Urinary protein profiles via proteomics

    Time frame: From baseline to 4 and 26 weeks of treatment

  4. Changes in blood concentration markers

    Changes in blood (serum and plasma) concentrations of potassium, creatinine, neutrophil gelatinase-associated lipocalin (NGAL), renin, angiotensin II, aldosterone, and kidney injury molecule-1 (KIM-1).

    Time frame: From baseline to 4 and 26 weeks of treatment

  5. Changes in urinary concentration markers

    Changes in urinary concentration of sodium, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1)

    Time frame: From baseline to 4 and 26 weeks of treatment

  6. Changes in UACR

    Changes in UACR

    Time frame: From baseline to 4 and 26 weeks.

08

Study locations

2 of 2 sites recruiting
  • Delphinium
    Groningen, Provincie Groningen 9713GZ, Netherlands
    Recruiting
  • University Medical Center Groningen
    Groningen, Provincie Groningen 9713GZ, Netherlands
    Recruiting
    • Kevin Damman, Associate Professor · Contactk.damman@umcg.nl · +31 (0)50 361 11255
    • Kevin Damman, Associate Professor · Principal investigator
09

References and documents

Individual participant data

Plan to share: Undecided — will be updated at a later stage

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 21 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 26, 2025
StartActual
May 12, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07304817
Collaborators
Boehringer Ingelheim, DELPHINIUM
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
May 12, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
May 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion